Lyra Therapeutics Confirms Nasdaq Delisting, Trading Suspension Imminent
summarizeSummary
Lyra Therapeutics, Inc. announced the withdrawal of its appeal against Nasdaq's delisting determination, confirming that trading in its common stock will be suspended on March 17, 2026.
check_boxKey Events
-
Delisting Confirmed
Lyra Therapeutics, Inc. has withdrawn its appeal of Nasdaq's delisting determination, finalizing its removal from the exchange.
-
Trading Suspension Imminent
Trading in the company's common stock on Nasdaq will be suspended at the open of trading on Tuesday, March 17, 2026.
-
Form 25 Filing
Nasdaq will file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission after all internal procedural periods have run.
auto_awesomeAnalysis
Lyra Therapeutics, Inc. has confirmed its imminent delisting from Nasdaq, a critical event that fundamentally alters the investment thesis. The company's decision to withdraw its appeal of the delisting determination signals the finality of its removal from the exchange. This will severely impact the stock's liquidity and visibility, making it significantly harder for investors to trade shares. Trading will be suspended on March 17, 2026, which is a definitive step towards the stock moving to over-the-counter markets, if at all, where trading is often less transparent and less liquid. This development comes as the stock is already trading near its 52-week low, underscoring the severe challenges the company faces.
At the time of this filing, LYRA was trading at $0.40 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.48 to $37.50. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.